This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Arita, Kihara, Ouchi, Takahashi, Maeda, Miyagawa, Hotta, Shimomura, Nakamura, Miyaoka, Kuriyama, Nishida, Yamashita, Okubo, Matsubara, Muraguchi, Ohmoto, Funahashi, Matsuzawa: "Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity." in: Biochemical and biophysical research communications, Vol. 257, Issue 1, pp. 79-83, (1999) (PubMed).
Saito, Tobe, Minoshima, Asakawa, Sumiya, Yoda, Nakano, Shimizu, Tomita: "Organization of the gene for gelatin-binding protein (GBP28)." in: Gene, Vol. 229, Issue 1-2, pp. 67-73, (1999) (PubMed).
Schäffler, Orsó, Palitzsch, Büchler, Drobnik, Fürst, Schölmerich, Schmitz et al.: "The human apM-1, an adipocyte-specific gene linked to the family of TNF's and to genes expressed in activated T cells, is mapped to chromosome 1q21.3-q23, a susceptibility locus identified for ..." in: Biochemical and biophysical research communications, Vol. 260, Issue 2, pp. 416-25, (1999) (PubMed).
ADIPOQ (Adiponectin) is an important negative regulator in hematopoiesis and immunesystems. ADIPOQ may be involved in ending inflammatory responses through its inhibitory functions. ADIPOQ inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway. It inhibits TNF-alpha-induced expression of endothelial adhesion molecules. ADIPOQ is involved in the control of fat metabolism and insulin sensitivity. Defects in ADIPOQ are the cause of adiponectin deficiency. The result is a very low concentration of plasma adiponectin. The decreased adiponectin plasma levels are associated with obesity insulin resistance, and diabetes type 2.